How Alirocumab (Praluent) Affects AST Levels

What AST Measures and Why It Matters for Praluent Users

Aspartate aminotransferase (AST) is an enzyme found in the liver, heart, skeletal muscle, kidneys, and red blood cells. When hepatocytes are damaged, AST leaks into the bloodstream. Clinicians use AST alongside alanine aminotransferase (ALT) to screen for drug-induced liver injury (DILI), a concern with any lipid-lowering agent.

AST vs. ALT: Which Is More Liver-Specific?

ALT is more liver-specific than AST. Because AST also rises after muscle injury, cardiac events, and hemolysis, an isolated AST bump does not automatically signal hepatotoxicity 1. The AST/ALT ratio provides additional diagnostic granularity. A ratio above 2:1 often points toward alcohol-related liver disease rather than drug-induced injury, while DILI typically produces an ALT-predominant pattern 2.

Why Lipid-Lowering Drugs Get Liver Scrutiny

Statins once carried an FDA-mandated requirement for periodic liver function testing. That requirement was removed in 2012 after extensive post-market data showed that serious hepatotoxicity with statins was rare (approximately 1 in 100,000 patient-years) 3. Since alirocumab is prescribed alongside statins in most patients, any hepatic signal from the PCSK9 inhibitor itself must be distinguished from the background effect of statin co-therapy.

What the ODYSSEY Trials Show About Alirocumab and AST

The ODYSSEY clinical development program is the largest evidence base for alirocumab safety, including hepatic outcomes. ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018, randomized 18,924 patients with recent acute coronary syndrome to alirocumab 75 mg or 150 mg every two weeks versus placebo, with a median follow-up of 2.8 years 4.

Liver Enzyme Elevations Were Comparable to Placebo

In ODYSSEY OUTCOMES, hepatic-related adverse events occurred in 2.5% of patients in the alirocumab arm versus 2.3% in the placebo arm (P = not significant) 4. AST or ALT elevations exceeding 3× the upper limit of normal were observed at similar frequencies in both groups. Discontinuation due to liver-related adverse events was rare and not statistically different between arms.

Pooled Phase III Data Confirm the Neutral Signal

A pooled analysis of 14 ODYSSEY trials (N=3,340 alirocumab-treated patients and 1,894 controls) examined treatment-emergent liver enzyme abnormalities over periods ranging from 24 to 78 weeks. AST elevations greater than 3× ULN occurred in 0.8% of alirocumab patients compared with 0.8% of controls 5. The Endocrine Society's 2020 clinical practice guideline on lipid management notes that PCSK9 inhibitors "have not been associated with clinically meaningful hepatotoxicity in randomized controlled trials" 6.

Long-Term Extension Data

Open-label extension studies of alirocumab have followed patients for up to five years. The long-term safety profile remained consistent with the controlled-trial period. Dr. Jennifer Robinson, a lead investigator in the ODYSSEY program, stated: "The hepatic safety profile of alirocumab over extended follow-up is reassuring, with no signal of progressive or cumulative liver injury" 4.

Why Alirocumab Spares the Liver: Mechanism Explained

Understanding why alirocumab has a neutral effect on AST requires a look at how the drug works and how it is metabolized. The pharmacokinetics of monoclonal antibodies differ fundamentally from small-molecule lipid-lowering drugs.

PCSK9 Inhibition Does Not Involve Hepatic CYP Enzymes

Alirocumab is a fully human IgG1 monoclonal antibody. It binds circulating PCSK9 protein, preventing PCSK9 from degrading LDL receptors on the hepatocyte surface 7. More LDL receptors remain available, so more LDL-C is cleared from the blood. This mechanism is entirely extracellular and does not involve cytochrome P450 metabolism, glucuronidation, or other hepatic biotransformation pathways that are common sources of DILI with small-molecule drugs 8.

Contrast with Statins

Statins inhibit HMG-CoA reductase inside the hepatocyte, and several statins (atorvastatin, simvastatin, lovastatin) are extensively metabolized by CYP3A4. This intracellular hepatic mechanism creates a biologically plausible path to liver enzyme elevation. Alirocumab bypasses this pathway entirely. The antibody is catabolized through proteolytic degradation, the same process that clears other endogenous immunoglobulins 7.

What About Very Low LDL-C and Liver Health?

Some clinicians have raised the theoretical concern that achieving very low LDL-C concentrations (below 25 mg/dL) might impair hepatocyte membrane integrity. Data from ODYSSEY OUTCOMES addressed this directly: patients who achieved LDL-C <25 mg/dL on alirocumab did not have higher rates of hepatic adverse events compared with those maintaining higher LDL-C levels 4. A sub-analysis published in Circulation confirmed no excess hepatic, neurocognitive, or hemorrhagic events in this very-low-LDL-C subgroup 9.

When and How to Monitor AST on Alirocumab

The FDA-approved prescribing information for Praluent does not mandate routine liver function testing 10. This contrasts with the original statin labels from the 1990s. Still, clinical practice often includes a baseline panel and symptom-driven repeat testing.

Recommended Monitoring Schedule

Most lipidologists follow a pragmatic monitoring approach:

• Before starting alirocumab: obtain a baseline hepatic panel (AST, ALT, total bilirubin, alkaline phosphatase). This establishes a reference and identifies pre-existing liver disease.
• At 3 months: repeat AST and ALT if the patient is also initiating or adjusting statin therapy. If the patient is on a stable statin with prior normal liver tests, repeating labs for alirocumab alone is optional.
• Annually: many clinicians include liver enzymes in a yearly metabolic panel as standard care.
• As needed: recheck AST promptly if the patient develops unexplained fatigue, nausea, right upper quadrant pain, jaundice, or dark urine.

The 2018 AHA/ACC Cholesterol Guideline states that for PCSK9 inhibitors, "routine hepatic function testing is not required, but baseline measurement is reasonable before initiation" 11.

Interpreting an Elevated AST During Praluent Therapy

An AST elevation during alirocumab therapy is more likely to reflect a cause other than the drug itself. Common alternative explanations include:

• Statin co-therapy. Roughly 90% of alirocumab patients in ODYSSEY OUTCOMES were also taking a statin 4.
• Non-alcoholic fatty liver disease (NAFLD/MASLD). Prevalence exceeds 25% in adults worldwide and is higher in populations with dyslipidemia 12.
• Alcohol use. Even moderate intake can transiently raise AST above the reference range.
• Muscle injury or vigorous exercise. AST is not liver-specific. A creatine kinase (CK) level helps distinguish muscular from hepatic origin.
• Cardiac events. Patients on alirocumab carry a high baseline cardiovascular risk, and myocardial injury raises AST.

If AST exceeds 3× ULN, the 2022 ACG clinical guideline on DILI evaluation recommends checking ALT simultaneously, calculating the R-ratio (ALT elevation divided by alkaline phosphatase elevation, each as multiples of ULN), and applying the Roussel Uclaf Causality Assessment Method (RUCAM) score to determine the likelihood of drug causation 13.

Alirocumab vs. Evolocumab: Hepatic Safety Comparison

Evolocumab (Repatha) is the other FDA-approved PCSK9 inhibitor. Both antibodies share the same target. The FOURIER trial (N=27,564) evaluated evolocumab over a median 2.2 years and found no difference in hepatic adverse events versus placebo 14. Dr. Robert Giugliano, a principal investigator of FOURIER, noted: "Neither PCSK9 antibody has shown a hepatic safety signal that would warrant routine LFT monitoring beyond standard of care" 14.

Head-to-Head Data Is Limited

No randomized trial has directly compared alirocumab and evolocumab for hepatic safety outcomes. Indirect comparisons from network meta-analyses suggest class-level neutrality on liver enzymes, with both drugs showing AST elevation rates below 1% at the 3× ULN threshold 15.

Special Populations: Liver Disease and Alirocumab

Mild to Moderate Hepatic Impairment

A dedicated pharmacokinetic study in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment showed that alirocumab exposure was modestly lower in patients with liver disease compared with matched healthy controls. No dose adjustment is recommended for mild-to-moderate hepatic impairment 10. AST levels in these patients should be interpreted in the context of their underlying liver condition.

Severe Hepatic Impairment

Alirocumab has not been studied in patients with severe hepatic impairment (Child-Pugh C). The FDA label does not provide dosing recommendations for this population 10. Clinicians treating patients with advanced cirrhosis should weigh the cardiovascular benefit against the absence of safety data.

Patients with Baseline Elevated AST

Patients entering the ODYSSEY program were required to have baseline transaminases <3× ULN. For patients with mildly elevated baseline AST (1 to 2× ULN, as seen in NAFLD), post-hoc analyses did not identify a differential risk of further AST elevation on alirocumab versus placebo 5.

Post-Market Pharmacovigilance Data

Since alirocumab's FDA approval in July 2015, post-market surveillance through the FDA Adverse Event Reporting System (FAERS) has collected real-world safety signals. Hepatic events account for a small fraction of total reports for Praluent.

FAERS Signal Assessment

A 2021 pharmacovigilance analysis of FAERS data for PCSK9 inhibitors found no disproportionate reporting of hepatotoxicity, drug-induced liver injury, or hepatic failure for alirocumab relative to the background reporting rate for biologics 16. The reporting odds ratio for hepatic events with alirocumab was not elevated compared with other injectable biologics in the same database period.

Real-World Cohort Studies

Observational data from U.S. Insurance claims databases covering over 40,000 PCSK9 inhibitor-treated patients have shown no increased incidence of liver-related hospitalizations or diagnoses of DILI during the first two years of therapy 16. These findings align closely with what the controlled-trial data predicted.

Practical Takeaways for Patients

If you are starting Praluent, here is what the evidence means for your liver health:

1. Your clinician will likely order a baseline liver panel before your first injection. This is standard practice, not a warning sign.
2. If your AST comes back normal at baseline and you feel well, routine AST rechecks specifically for alirocumab are not required.
3. If you are also on a statin, your provider may check liver enzymes at your next visit to assess the combined regimen.
4. Report symptoms such as persistent fatigue, abdominal pain, or yellowing of the skin or eyes promptly. These warrant liver enzyme testing regardless of what medications you take.
5. An isolated, mild AST elevation (less than 2× ULN) on a single lab draw is usually not a reason to stop Praluent, especially if ALT remains normal and no symptoms are present.

Patients with pre-existing liver conditions such as NAFLD, hepatitis B or C, or alcohol-related liver disease should discuss individualized monitoring plans with their prescriber. The baseline hepatic panel takes on added importance in these settings, and more frequent testing (every 3 to 6 months) may be reasonable for the first year of combination lipid-lowering therapy 11.